期刊文献+

以异常能量代谢为靶点治疗恶性肿瘤的研究进展 被引量:8

Research advances in targeting abnormal energy metabolism for cancer treatment
在线阅读 下载PDF
导出
摘要 充足的能量及营养供应是癌细胞生长、浸润及转移的基础,能量代谢异常是癌细胞最显著的特征之一。癌细胞存在广泛的能量代谢异常包括蛋白质和脂肪代谢异常,而有氧糖酵解是癌细胞能量代谢的主要方式。近年来,以糖酵解、氨基酸及脂肪代谢关键酶或载体作为靶标对一些肿瘤进行分子靶向治疗取得了一些重要成果,具有广阔的临床应用前景。 Abundant energy and nutrition supply is essential for growth, filtration and metastasis of tumor cells. Tumor cells are known for their altered energy metabolism characteristics. Aerobic glycolysis, known as "Warburg effect",is the most recognized metabolic abnormality of tumor cells. In addition,protein and lipid metabolism is also reported abnormal in tumor cells. The abnormality of tumor cells provided novel possibilities to interfere tumor cell growth. Recently, targeting key metabolic enzymes in cancer treatment has made significant progresses and is showing a promising clinical prospect.
作者 刘小军 赵达
出处 《复旦学报(医学版)》 CAS CSCD 北大核心 2012年第6期676-679,共4页 Fudan University Journal of Medical Sciences
基金 中央高校基本科研业务费专项资助项目(lzujbky-2012-224) 兰州大学第一医院院内基金项目(ldyynjx 201112)~~
关键词 恶性肿瘤 糖酵解 能量代谢 malignant tumor aerobic glycolysis energy metabolism
  • 相关文献

参考文献1

  • 1Tian-Qi Liu,Jun Fan,Lin Zhou and Shu-Sen Zheng Key Laboratory of Combined Multi-organ Trans-plantation,Ministry of Public Health,Key Laboratory of Organ Trans-plantation,Zhejiang Province,and Division of Hepatobiliary and Pancreatic Surgery,Department of Surgery,State Key Laboratory for Diagnosis and Treatment of Infectious Disease,First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China,Department of Hepatobiliary Surgery,the People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021,China.Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells[J].Hepatobiliary & Pancreatic Diseases International,2011,10(1):72-77. 被引量:9

二级参考文献35

  • 1Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi[J].Hepatobiliary & Pancreatic Diseases International,2004,3(3):341-344. 被引量:11
  • 2Jemal A;Siegel R;Ward E.Cancer statistics,2009,2009.
  • 3A Jemal,R Siegel,E Ward,Y Hao,J Xu,T Murray.Cancer statistics,2008CA A Cancer Journal for Clinicians,2008.
  • 4Warburg O.On the origin of cancer cells. Science . 1956
  • 5El-Serag HB.Hepatocellular carcinoma: recent trends in the United States. Gastroenterology . 2004
  • 6Zheng SS,Xu X,Wu J,Chen J,Wang WL,Zhang M,et al.Liver transplantation for hepatocellular carcinoma:Hangzhou experiences. Transplantation . 2008
  • 7Yang L,Parkin D M,Ferlay J,et al.Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiology Biomarkers and Prevention . 2005
  • 8Jemal A,Siegel R,Xu Jet al.Cancer Statistics 2010. CA A Cancer Journal for Clinicians . 2010
  • 9Bernardino Rampone,Beniamino Schiavone,Giuseppe Confuorto.Current Management of Hepatocellular Cancer[J]. Current Oncology Reports . 2010 (3)
  • 10Chen WeiXing,Hu Tiantian,Ni Qun,Yu Chaohui,Xu Ping.Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells[J]. Medical Oncology . 2008 (1)

共引文献8

同被引文献69

  • 1KatherineDCrew,AlfredINeugut.Epidemiology of gastric cancer[J].World Journal of Gastroenterology,2006,12(3):354-362. 被引量:191
  • 2龚立鹏,张颖,张本华,刘文健,肖宝荣.乳酸脱氢酶与食管癌转移的临床研究[J].泰山医学院学报,2006,27(5):434-436. 被引量:5
  • 3Hirschhaeuser F, Sattler UG, Mueller-Klieser W. La- ctate:a metabolic key player in cancer[J]. Cancer Res,2011,71(22) :6921-6925.
  • 4Kim JW,Gao P,Liu YC,et al. Hypoxia-inducible fac tor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic swit ches hexokinase 2 and pyruvate dehydrogenase kinase 1[J]. Mol Cell Biol,2007,27(21) :7381-7393.
  • 5Hsu PP, Sabatini DM. Cancer cell metabolism: War burg and beyond[J]. Cell, 2008,134 (5) : 703-707.
  • 6Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Prognostic and predictive role of lactate dehydrogen ase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584(vatalanib) antiangiogenic thetapy[J]. Clin Cancer Res, 2011,17(14):4892- 4900.
  • 7Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenas predicts for overall survival benefit in patients with metastatic renal cell carcinoma treatedwith inhibition of mammalian target of rapamycin EJJ- J Clin Oncol,2012,30(27) :3402-3407.
  • 8Eigentler TK,Figl A,Krex D,et al. Number of me- tastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma[J]. Cancer, 2011,117 (8) :1697-1703.
  • 9Kolev Y, Uetake H, Takagi Y, et al. Lactate dehy- drogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-la) pathway, angiogenic factors productionand poor prognosis[J]. Ann Surg Oncol, 2008, 15 (8) : 2336-2344.
  • 10Lu H, Li X, Luo Z, et al. Cetuximab reverses the warburg effect by inhibiting HIF-l-regulated LDH- A[J]. Mol Cancer Ther,2013,12(10):2187-2199.

引证文献8

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部